188 related articles for article (PubMed ID: 18524423)
1. Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors.
Peifer C; Bühler S; Hauser D; Kinkel K; Totzke F; Schächtele C; Laufer S
Eur J Med Chem; 2009 Apr; 44(4):1788-93. PubMed ID: 18524423
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.
Peifer C; Selig R; Kinkel K; Ott D; Totzke F; Schächtele C; Heidenreich R; Röcken M; Schollmeyer D; Laufer S
J Med Chem; 2008 Jul; 51(13):3814-24. PubMed ID: 18529047
[TBL] [Abstract][Full Text] [Related]
3. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
4. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors.
Kitano Y; Suzuki T; Kawahara E; Yamazaki T
Bioorg Med Chem Lett; 2007 Nov; 17(21):5863-7. PubMed ID: 17869510
[TBL] [Abstract][Full Text] [Related]
6. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
8. Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
Ibrahim N; Mouawad L; Legraverend M
Eur J Med Chem; 2010 Aug; 45(8):3389-93. PubMed ID: 20472330
[TBL] [Abstract][Full Text] [Related]
9. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities.
Lücking U; Siemeister G; Schäfer M; Briem H; Krüger M; Lienau P; Jautelat R
ChemMedChem; 2007 Jan; 2(1):63-77. PubMed ID: 17131463
[TBL] [Abstract][Full Text] [Related]
10. Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Wang Y; Shakespeare WC; Huang WS; Sundaramoorthi R; Lentini S; Das S; Liu S; Banda G; Wen D; Zhu X; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Dalgarno D; Clackson T; Sawyer TK
Bioorg Med Chem Lett; 2008 Sep; 18(17):4907-12. PubMed ID: 18691885
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
Laufer SA; Domeyer DM; Scior TR; Albrecht W; Hauser DR
J Med Chem; 2005 Feb; 48(3):710-22. PubMed ID: 15689155
[TBL] [Abstract][Full Text] [Related]
13. N9-Substituted N⁶-[(3-methylbut-2-en-1-yl)amino]purine derivatives and their biological activity in selected cytokinin bioassays.
Mik V; Szüčová L; Spíchal L; Plíhal O; Nisler J; Zahajská L; Doležal K; Strnad M
Bioorg Med Chem; 2011 Dec; 19(23):7244-51. PubMed ID: 22019467
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.
Harris PA; Boloor A; Cheung M; Kumar R; Crosby RM; Davis-Ward RG; Epperly AH; Hinkle KW; Hunter RN; Johnson JH; Knick VB; Laudeman CP; Luttrell DK; Mook RA; Nolte RT; Rudolph SK; Szewczyk JR; Truesdale AT; Veal JM; Wang L; Stafford JA
J Med Chem; 2008 Aug; 51(15):4632-40. PubMed ID: 18620382
[TBL] [Abstract][Full Text] [Related]
15. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
[TBL] [Abstract][Full Text] [Related]
16. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
Renhowe PA; Pecchi S; Shafer CM; Machajewski TD; Jazan EM; Taylor C; Antonios-McCrea W; McBride CM; Frazier K; Wiesmann M; Lapointe GR; Feucht PH; Warne RL; Heise CC; Menezes D; Aardalen K; Ye H; He M; Le V; Vora J; Jansen JM; Wernette-Hammond ME; Harris AL
J Med Chem; 2009 Jan; 52(2):278-92. PubMed ID: 19113866
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of a new series of phenylhydroquinone derivatives as inhibitors of EGF-R-associated PTK activity.
Million ME; Mailliett P; Chen H; Bashiardes G; Boiziau J; Parker F; Commerçon A; Tocque B; Roques BP; Garbay C
Anticancer Drug Des; 1996 Mar; 11(2):129-53. PubMed ID: 8630186
[TBL] [Abstract][Full Text] [Related]
18. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase.
Rodríguez-Franco MI; Fernández-Bachiller MI; Pérez C; Castro A; Martínez A
Bioorg Med Chem; 2005 Dec; 13(24):6795-802. PubMed ID: 16183292
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
